electroCore (ECOR) vs Nuwellis (NUWE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
electroCore is the larger company by market cap ($40.8 million vs $1.8 million), about 22.1 times the size. electroCore converts more of its revenue into profit, with a net margin of -43.6% versus -211.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ECOR | NUWE |
|---|---|---|
| Share price | $4.42 | $3.41 |
| Market cap | $40.78M | $1.84M |
| 1-day change | -8.87% | -10.50% |
| YTD return | -1.45% | — |
| 1-year return | -6.16% | — |
| 5-year return | -61.23% | — |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-1.36 | $3,609.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $32.03M | $8.27M |
| Revenue growth (YoY) | +27.20% | -5.38% |
| Net income (latest FY) | $-13.97M | $-17.52M |
| Gross margin | 86.75% | 61.96% |
| Operating margin | -41.06% | -134.29% |
| Net margin | -43.60% | -211.86% |
| 52-week high | $12.70 | $1,556.10 |
| 52-week low | $3.90 | $2.52 |
| Distance from 52-week high | -65.20% | -99.78% |
| Analyst consensus | none | — |
| Avg. price target upside | +333.71% | — |
| Average volume | 120.32K | 829.19K |
| Shares outstanding | 9.23M | 540.91K |
| Employees | 83 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- electroCore is about 22.1 times larger than Nuwellis by market value ($40.78M vs $1.84M).
- electroCore is more profitable, keeping -43.6 cents of every revenue dollar as net income versus -211.9 cents for Nuwellis.
- electroCore grew revenue faster in its latest fiscal year (+27.20% vs -5.38%).
About electroCore
ECOR stock →electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 83 employees
About Nuwellis
NUWE stock →Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 38 employees
ECOR vs NUWE FAQ
Which is bigger, electroCore or Nuwellis?
electroCore (ECOR) is larger, with a market capitalization of $40.78M compared with $1.84M for Nuwellis (NUWE).
Are electroCore and Nuwellis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.